MSD has announced long-term maintenance results from GO-COLITIS.
List view / Grid view
Filter the results
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
9 February 2016 | By Victoria White
The committee was unable to accept eculizumab as it was "not considered to represent an effective use of NHS Scotland’s resources"...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
26 June 2015 | By Victoria White
The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)...
Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
CHMP adopts positive opinion of Simponi for the treatment of non-radiographic axial spondyloarthritis
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
New data at ACR meeting show efficacy of Simponi® (golimumab) in treating patients with active non-radiographic axial spondyloarthritis
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...